EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

Coherus Oncology formally introduces non-proprietary name: tagmokitug--Publication shows picomolar affinity for CCR8 with no off-target binding ...

The devastating consequences of mucopolysaccharidosis II (MPS II), also called Hunter syndrome, may soon become preventable ...

New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep’s development as a platform immunotherapy across GI tumorsCompany continues to strengthen its clinical ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use ...

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive ...

After several years of rapid experimentation, AI will enter a new chapter in 2026 that resembles an industry rather than an extended research cycle.

To Jagannath, cure means long periods of disease-free survival as defined by minimal residual disease (MRD) criteria, 10 -5 ...

As clinical trials race against time, especially during global health emergencies, data-driven patient enrollment has become ...

A randomized clinical trial published in Autism Research finds that cannabidiol (CBD) combined with terpenes may help reduce ...